Anzeige
Mehr »
Login
Dienstag, 01.04.2025 Börsentäglich über 12.000 News von 695 internationalen Medien
Kurs-Explosion voraus?: Diese kaum bekannte Aktie bohrt jetzt im Hotspot - und du erfährst es als Erster!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QCFW | ISIN: US04746L1044 | Ticker-Symbol:
NASDAQ
01.04.25
20:38 Uhr
0,260 US-Dollar
-0,025
-8,70 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ATHIRA PHARMA INC Chart 1 Jahr
5-Tage-Chart
ATHIRA PHARMA INC 5-Tage-Chart

Aktuelle News zur ATHIRA PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
27.02.Athira Pharma, Inc. - S-8, Securities to be offered to employees in employee benefit plans16
04.01.Athira Pharma, Inc. (NASDAQ:ATHA) CEO Mark James Litton Sells 25,107 Shares11
06.12.24Athira Pharma, Inc.: Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND270BOTHELL, Wash., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and...
► Artikel lesen
08.11.24Athira exploring strategic alternatives after Alzheimer's failure10
ATHIRA PHARMA Aktie jetzt für 0€ handeln
08.11.24Athira Pharma GAAP EPS of -$0.75 misses by $0.042
07.11.24Athira Pharma, Inc.: Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates218BOTHELL, Wash., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and...
► Artikel lesen
07.11.24Athira Pharma, Inc. - 8-K, Current Report2
01.11.24Pre-market Movers: ESSA Pharma, Theriva Biologics, VS MEDIA, Lexicon Pharmaceuticals, Athira Pharma1.106CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.00 A.M. ET).In the Green Theriva Biologics, Inc. (TOVX) is up over 47% at $2.15. VS...
► Artikel lesen
18.10.24Athira Pharma faces Nasdaq delisting over share price12
18.10.24Athira Pharma, Inc. - 8-K, Current Report8
01.08.24Athira Pharma, Inc.: Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates173Topline data from completed Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer's disease targeted for September 2024 Phase 2/3...
► Artikel lesen
11.06.24Athira Pharma, Inc.: Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)144BOTHELL, Wash., June 11, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
► Artikel lesen
15.05.24Athira Pharma, Inc.: Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates539Topline data from Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer's disease expected in second half of 2024 Submitted Investigational New...
► Artikel lesen
15.04.24Athira Pharma, Inc.: Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer473BOTHELL, Wash., April 15, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
► Artikel lesen
11.04.24Athira Pharma, Inc.: Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease401BOTHELL, Wash., April 11, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
► Artikel lesen
15 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1